Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Active, not recruiting · NCT02704858 · Registry updated 2026-09-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT02704858 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Neonc Technologies, Inc. | 4 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Atlantic Health (Overlook Medical Center) | Summit | United States | 1 |
| Baylor Scott & White Health | Dallas | United States | 1 |
| Cleveland Clinic | Cleveland | United States | 1 |
| Georgia Cancer Center (Augusta University) | Augusta | United States | 1 |
| Northwell Health | New York | United States | 2 |
| Ochsner Health | New Orleans | United States | 9 |
| Saint John Cancer Institute | Santa Monica | United States | 2 |
| Sutter Health Research Institute | San Francisco | United States | 2 |
| University of Southern California | Los Angeles | United States | 110 |
| University of Texas Southwestern Medical Center | Dallas | United States | 18 |
| Wake Forest University Health Sciences | Winston-Salem | United States | 330 |